Short Answer

Both the model and the market expect Trump to make IVF free before 2029, with no compelling evidence of mispricing.

1. Executive Verdict

  • Trump's 2024 campaign pledged to make IVF "free" or mandate insurance.
  • His administration pursues executive actions and legislative efforts for IVF affordability.
  • The Trump administration proposed new 'excepted benefits' for fertility treatments May 10, 2026.
  • This proposed rule is projected to nearly double employer-sponsored IVF coverage.
  • A single IVF cycle typically costs $15,000 to $25,000 out-of-pocket.

Who Wins and Why

Outcome Market Model Why
Before 2029 14.0% 6.6% Trump's future policy considerations may include making IVF services free before 2029.

Current Context

Trump has not made IVF free, pursuing voluntary benefits instead. As of May 2026, President Trump has not fulfilled his 2024 campaign pledge to make IVF free [^][^][^][^]. Instead, his administration has shifted focus to encouraging voluntary employer-provided fertility benefits and reducing medication costs [^][^][^][^]. A key action was the proposed rule on May 10, 2026, which would permit employers to offer standalone fertility benefits as "excepted benefits" [^][^][^][^]. This initiative aims to expand access without federal mandates by capping these benefits at a $120,000 lifetime maximum [^][^][^][^].
Administration initiatives prioritize employer benefits and medication cost reduction. Previous administration actions include the launch of TrumpRx.gov in early 2026 to provide discounts on certain fertility medications [^][^][^]. This platform was established following an executive order issued in February 2025 [^][^][^]. However, experts and advocacy groups, such as the American Society for Reproductive Medicine, have expressed skepticism regarding the effectiveness of these voluntary measures [^][^][^][^]. They note that such approaches do not guarantee universal access or cover the full scope of IVF procedural costs [^][^][^][^].

2. Market Behavior & Price Dynamics

Historical Price (Probability)

Outcome probability
Date
This prediction market has exhibited a stable, sideways trend within a very narrow range of 14.0% to 17.0%. The chart indicates a single, distinct price movement where the probability dropped from its starting point of 17.0% down to 14.0%. Since this shift, the price has remained flat, establishing 14.0% as a firm support level and suggesting a stable market consensus. The total trading volume of 733 contracts is relatively low, and the lack of volume in recent data points suggests that trading activity has subsided since the price found its new level.
The primary price drop from 17.0% to 14.0% appears to be a direct reaction to recent developments. Around the time of the price change, news reports indicated that the Trump administration was not pursuing a policy to make IVF free. Instead, the administration is reported to have proposed a new rule focused on encouraging employers to voluntarily offer fertility benefits. This policy pivot, which moves away from the direct action required for a "YES" resolution in this market, likely caused traders to reassess the probability downwards, leading to the price settling at the current 14.0% level.
Overall, market sentiment is strongly pessimistic regarding the likelihood of Trump making IVF free before his term ends. The initial 17.0% probability was already low, and the drop to 14.0% following the policy news solidified this skepticism. The subsequent flat price action and low volume indicate that the market has priced in this new policy direction and has reached a consensus that the specific terms of the prediction are very unlikely to be met.

3. Market Data

View on Kalshi →

Contract Snapshot

This market resolves to "Yes" if the President takes action that eliminates the cost of at least one IVF cycle before January 20, 2029, based on information from official and journalistic sources. If this action does not occur by January 19, 2029, at 11:59 PM EST, the market will resolve to "No." The market opened on July 8, 2025, may close early if the "Yes" event occurs, and prohibits insider trading by persons employed by Source Agencies or those with material, non-public information.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before 2029 $0.15 $0.86 14%

Market Discussion

The discussion largely centers on the unlikelihood of "Yes" due to the strict interpretation of the market rules, which require a full IVF cycle to be totally free nationwide—a policy seen as politically impossible, needing significant congressional funding, and unpopular within Trump's base. Arguments for "No" highlight the massive jump from current discussions to full cost elimination. While some users express hope for a "Yes" resolution, the primary question from that perspective is whether Medicaid coverage alone would qualify as making IVF "free," indicating uncertainty about the scope of the rule.

4. What legislative or executive pathways could the Trump administration pursue to make IVF 'free' before 2029?

Proposed Fertility Benefit Plan Cap$120,000 lifetime cap (May 2026) [^][^][^]
IVF Medication Discount ProgramTrumpRx.gov launched in early 2026 [^][^][^]
Federal IVF Legislation StatusNot enacted as of May 2026 [^][^][^]
The Trump administration uses executive actions to enhance IVF affordability. The administration has supported legislative and executive efforts to increase the affordability and access to IVF, though these measures do not make IVF 'free' for all patients [^][^][^]. Current pathways primarily focus on reducing out-of-pocket costs through employer benefits and medication discounts, rather than mandating free access [^][^][^][^][^][^]. A proposed rule from May 2026 would allow employers to offer voluntary 'limited excepted' fertility benefit plans, which could include a lifetime cap of $120,000 [^][^][^]. Additionally, TrumpRx.gov was launched in early 2026 to provide negotiated discounts on specific IVF medications via agreements with manufacturers like EMD Serono, directly aiming to reduce patient expenses [^][^][^].
Legislative efforts for IVF access remain un-enacted as of May 2026. Federal legislation, such as H.R. 1878 and H.R. 8119, has been introduced to address IVF access and insurance mandates [^][^][^]. However, as of May 2026, these bills have not been enacted into law [^][^][^]. The available information does not describe additional legislative or executive pathways the Trump administration could pursue to make IVF 'free' before 2029, beyond these current efforts to enhance affordability and reduce costs.

5. How does the estimated cost reduction from Trump's 2026 policies compare to the average out-of-pocket cost for a full IVF cycle?

Estimated IVF Cost Reduction$2,000 to $2,200 (TrumpRx.gov) [^][^][^][^][^]
Average Out-of-Pocket IVF Cost$15,000 to $25,000 (per cycle) [^][^][^][^][^][^]
Reduction Percentage8% to 15% of total IVF cost [^][^][^]
Average out-of-pocket IVF costs are substantial in the U.S. A single cycle of in vitro fertilization (IVF) typically costs between $15,000 and $25,000 in the United States, with some totals exceeding $30,000 when accounting for necessary medications, genetic testing, and various add-on services [^][^][^][^][^][^].
The TrumpRx.gov initiative provides specific fertility medication discounts. This program, launched in February 2026, aims to lower the cost of certain fertility medications through Most-Favored-Nation pricing agreements [^][^][^][^][^]. This initiative is estimated to reduce the overall cost of an IVF cycle by approximately $2,000 to $2,200 [^][^][^][^][^]. This reduction translates to roughly 8% to 15% of the total expense for a standard IVF cycle, given that medications typically constitute about 20% of the complete cost [^][^][^].
Significant additional IVF cost reductions appear unlikely currently. Despite these initial savings, prediction markets currently indicate a low probability, around 20%, that the Trump administration will implement policies to make IVF entirely free before the conclusion of its term [^][^][^].

6. How does the Trump administration's proposed 'excepted benefits' framework compare to existing state-level IVF insurance mandates?

Proposal DateMay 10, 2026 [^]
Lifetime Maximum$120,000 per participant [^]
Benefit NatureVoluntary, employer-sponsored [^]
The Trump administration proposed new 'excepted benefits' for fertility treatments on May 10, 2026. This rule aims to create a category of limited excepted benefits, enabling employers to offer standalone fertility coverage that is exempt from many Affordable Care Act (ACA) market reforms [^].
This framework is voluntary, not a federal IVF mandate, for employers [^] . In contrast to state-level IVF mandates that often integrate fertility services into comprehensive health plans, the administration's proposal focuses on employer-sponsored, standalone, voluntary benefits. These benefits would operate outside of major medical plan requirements and include a cap of $120,000 lifetime maximum per participant, with inflation indexing commencing in 2028 [^][^][^][^].

7. What data is available to track employer adoption of the 'excepted benefits' for IVF following the Department of Labor's May 2026 rule?

Proposed Rule DateMay 10, 2026 [^][^][^][^]
Proposed Effective DateJanuary 1, 2027 (for plan years) [^][^][^][^][^][^]
Employer Fertility Benefits (pre-proposal)42% of U.S. organizations in 2024 [^][^]
Federal agencies proposed a new pathway for fertility benefits in May 2026. On May 10, 2026, the U.S. Departments of Labor, Health and Human Services, and the Treasury proposed a rule to establish certain fertility benefits as a new category of limited excepted benefits [^][^][^][^]. This proposal would enable employers to offer these benefits outside of major medical coverage requirements for plan years beginning on or after January 1, 2027 [^][^][^][^][^][^].
Specific federal data for tracking excepted benefits adoption is currently unavailable. As the rule is still in the proposed stage, there is no specific, centralized federal data available to track employer adoption of this new 'excepted benefits' pathway for IVF [^][^]. While industry data from the International Foundation of Employee Benefit Plans (IFEBP) indicated that 42% of U.S. organizations offered some fertility benefits in 2024, this data tracks general fertility benefit adoption prior to the May 2026 proposal, rather than the specific new excepted benefits framework [^][^].

8. What is the projected impact of the May 2026 'excepted benefits' rule on the number of Americans with employer-sponsored IVF coverage?

Projected increase in employersfrom 268,000 to 523,000 (annual) [^]
Additional enrollees (annual)Up to 750,000 (annual) [^]
Lifetime benefit cap$120,000 per participant [^][^][^]
The May 2026 rule significantly expands employer-sponsored fertility coverage. This proposed rule is projected to nearly double the number of employers offering fertility benefits, increasing from approximately 268,000 to 523,000. This expansion could also enable up to 750,000 additional individuals to enroll in such coverage annually, broadening access to fertility care [^].
The rule establishes a new 'limited excepted benefits' category for fertility. Specifically, it allows employers to offer standalone fertility coverage, which includes IVF, independently of certain Affordable Care Act (ACA) market reforms [^][^][^]. This type of coverage would typically include a lifetime benefit cap of $120,000 per participant [^][^][^].
The proposal creates a voluntary, employer-based IVF coverage pathway. The available information clarifies that this initiative is a voluntary, employer-based program and not a federal mandate or government-funded program [^][^][^][^]. Consequently, critics and analysts suggest that this approach does not fully address a campaign promise to make IVF "free for all Americans," leaving the related prediction market question unresolved [^][^][^][^].

9. What Could Change the Odds

Key Catalysts

President Trump's 2024 campaign pledge was to make IVF "free" or mandate insurance coverage [^] [^] [^] . However, his administration has not implemented this as a universal mandate; instead, it has pursued a policy of encouraging voluntary employer-sponsored fertility benefits [^][^][^].
The administration's approach includes a proposed rule (announced May 2026) to allow employers to offer standalone fertility benefits as "limited excepted benefits," similar to dental or vision insurance [^] [^] [^] . Trump Announces Actions to Lower Costs and Expand Access to In Vitro Fertilization (IVF) and High-Quality Fertility Care – The White House">[^][^][^]. This also includes a drug-pricing agreement (TrumpRx.gov) to provide discounts on select IVF medications [^][^][^]. This policy framework relies on voluntary employer participation rather than federal subsidies or universal mandates, with officials aiming for these new benefit options to be available for the 2027 health insurance plan year [^][^][^].
While prediction markets have tracked various fertility-related outcomes, there is no evidence of a specific, active, or high-volume prediction market betting on the fulfillment of a "free IVF" mandate, as the administration's actual policy path has diverged from the campaign rhetoric of a universal mandate [^].

Key Dates & Catalysts

  • Expiration: January 27, 2029
  • Closes: January 20, 2029

10. Decision-Flipping Events

  • Trigger: President Trump's 2024 campaign pledge was to make IVF "free" or mandate insurance coverage [^] [^] [^] .
  • Trigger: However, his administration has not implemented this as a universal mandate; instead, it has pursued a policy of encouraging voluntary employer-sponsored fertility benefits [^] [^] [^] .
  • Trigger: The administration's approach includes a proposed rule (announced May 2026) to allow employers to offer standalone fertility benefits as "limited excepted benefits," similar to dental or vision insurance [^] [^] [^] .
  • Trigger: This also includes a drug-pricing agreement (TrumpRx.gov) to provide discounts on select IVF medications [^] [^] [^] .

12. Historical Resolutions

No historical resolution data available for this series.